TNF抑制剂治疗对类风湿关节炎关节置换率的影响:BSRBR-RA登记匹配队列分析
基于英国风湿病学会生物制剂登记(BSRBR-RA,2001-2016)的倾向评分匹配队列分析,共纳入19 116例患者记录,比较TNF抑制剂(TNFi)与传统合成DMARDs对关节置换发生率的影响。总体未发现TNFi与全髋置换(THR)或全膝置换率显著相关,但年龄存在显著效应修饰(P<0.001),>60岁患者中TNFi与THR风险降低相关(HR=0.60,95%CI 0.41-0.87)。
要点
- 总体TNFi使用与关节置换发生率无显著关联。
- 年龄显著修饰TNFi对THR的影响(P<0.001)。
- >60岁患者中TNFi与THR风险降低40%相关(HR=0.60)。
核心结论
- 总体未发现TNFi使用与后续关节置换发生率存在显著关联。
- 在>60岁患者中,TNFi与全髋置换率相对降低40%相关。
研究设计与样本
- 采用倾向评分匹配队列分析,数据来自英国风湿病学会生物制剂登记(BSRBR-RA)2001-2016年RA数据。
- TNFi使用者按1:1比例与相似的传统合成DMARDs使用者匹配(有放回),匹配分析共包含19 116例患者记录。
- 使用加权多变量Cox回归估计TNFi对研究结局的影响,并分析基线年龄和疾病严重程度的效应修饰。
- 还分析了其他部位关节置换,并进行了工具变量敏感性分析。
主要发现
- TNFi使用与THR发生率总体无显著关联(HR=0.86,95%CI 0.60-1.22)。
- 年龄对TNFi与THR的关联存在显著效应修饰(P<0.001)。
- >60岁患者中TNFi与THR风险降低相关(HR=0.60,95%CI 0.41-0.87),年轻患者中无此关联。
- TNFi与全膝置换或其他部位关节置换均无显著关联。
关键数值与推荐
- THR总体HR=0.86(95%CI 0.60-1.22),TNFi vs 传统合成DMARDs。
- >60岁患者THR的HR=0.60(95%CI 0.41-0.87),TNFi vs 传统合成DMARDs。
- 年龄效应修饰P<0.001。
临床怎么用
- 对于>60岁RA患者,TNFi治疗可能与全髋置换需求降低相关,可结合年龄因素评估关节置换风险。
- 总体关节置换风险未因TNFi使用而显著改变,临床决策仍需综合评估。
局限性
- 既往缺乏患者水平数据,本研究为观察性匹配队列分析,可能存在残余混杂。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Previous ecological data suggest a decline in the need for joint replacements in RA patients following the introduction of TNF inhibitor (TNFi) therapy, although patient-level data are lacking. Our primary aim was to estimate the association between TNFi use and subsequent incidence of total hip replacement (THR) and total knee replacement. METHODS: A propensity score matched cohort was analysed using the British Society for Rheumatology Biologics Registry (2001-2016) for RA data. Propensity score estimates were used to match TNFi users to similar conventional synthetic DMARD users (with replacement) using a 1:1 ratio. Weighted multivariable Cox regression was used to estimate the impact of TNFi on study outcomes. Effect modification by baseline age and disease severity were investigated. Joint replacement at other sites was also analysed. An instrumental variable sensitivity analysis was also performed. RESULTS: The matched analysis contained a total of 19 116 patient records. Overall, there was no significant association between TNFi use vs conventional synthetic DMARD on rates of THR (hazard ratios = 0.86 [95% CI: 0.60, 1.22]) although there was significant effect modification by age (P < 0.001). TNFi was associated with a reduction in THR among those >60 years old (hazard ratio = 0.60 [CI: 0.41, 0.87]) but not in younger patients. No significant associations were found for total knee replacement or other joint replacement. CONCLUSION: Overall, no association was found between the use of TNFi and subsequent incidence of joint replacement. However, TNFi was associated with a 40% relative reduction in THR rates among older patients.
引用
- Hawley S, Ali MS, Cordtz R, et al. Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology (Oxford). 2019. PMID: 30649521. doi:10.1093/rheumatology/key424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。